ophthotech
Phase 3 eye drug combo failure for Novartis
December 12, 2016Research and Development, Sales and Marketing Novartis, ophthotech
Novartis’ has failed in its attempt to expand the applications of its anti-VEGF eye treatment Lucentis (ranibizumab) after the drug …
Novartis pays $200m for eye technology
May 22, 2014Sales and Marketing Novartis, eye technology, fovista, ophthotech, wet and
Novartis has bought the rights to licence and commercialise a novel anti-PGDF therapy which it is currently trialling in Phase …
Latest content
Acumentis CEO Herspiegel steps down as Burden assumes role
October 27, 2026
October 26, 2026
